Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World May 14, 2014 Andy Extance	Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca.
Chemistry World February 12, 2015 Rebecca Trager	Hospira buyout is a shot in the arm for Pfizer's biosimilars Pfizer said in a statement that its acquisition of Hospira will create 'a leading global sterile injectables business.
Chemistry World April 29, 2014 Phillip Broadwith	Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.
The Motley Fool April 19, 2006 Brian Gorman	Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.
The Motley Fool July 20, 2005 Stephen D. Simpson	Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
Chemistry World February 4, 2010 Matt Wilkinson	More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets.
Chemistry World June 24, 2011 Andrew Turley	Pfizer to Keep 350 Jobs at Sandwich US drug giant Pfizer has said that it will keep 350 jobs at its site in Sandwich, UK.
The Motley Fool October 20, 2006 Brian Lawler	Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth.
The Motley Fool February 2, 2011 Brian Orelli	Pfizer's Newest Acquisition Target The pharma giant decided to cut potential acquisitions from its revenue guidance and instead spend the money on share buybacks.
Chemistry World May 28, 2014 Phillip Broadwith	Time called on Pfizer -- AstraZeneca deal Pfizer's pursuit of a pharmaceutical megamerger has concluded with the US giant withdrawing its final offer two hours before the deadline set by the UK's takeover rules.
The Motley Fool January 14, 2008 Brian Lawler	Worst Stock for 2008: Pfizer This analyst thinks that Pfizer is a good company, but a bad stock for 2008.
The Motley Fool June 20, 2011 Luke Timmerman	Pfizer's Idea to Fix the Drug Development Crisis, Which Probably Won't Work (But Just Might) In a worst-case scenario, Pfizer flushes a few hundred million dollars down the tubes. What's the best-case scenario?
The Motley Fool February 22, 2007 Brian Lawler	Dueling Fools: Pfizer Bear It's been a blue chip for years, but that doesn't mean it will stay that way forever. It's inconceivable for Pfizer's market capitalization to be valued at $188 billion four years from now, when its revenues could be 40% lower than they are today.
Chemistry World February 2, 2011 Andy Extance	Pfizer to close historic UK site Most of the 2400 people employed at the Pfizer site in Sandwich, UK, will be made redundant over the next 18-24 months as the US pharma giant restructures its research operations.
Chemistry World August 3, 2012 Andrew Turley	Pfizer secures Sandwich buyer Pfizer has found a buyer for its R&D site in Sandwich, UK: the site -- now called Discovery Park -- has been bought by a private consortium, according to Kent County Council.
The Motley Fool December 14, 2005 Steven Mallas	Pfizer: Of Drugs and Dividends Pfizer is raising its payout. Is it a good move for the drugmaker? Investors willing to hold for years while reinvesting dividends will most likely be rewarded along the way.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull The drug giant has ample firepower. The current company valuation largely ignores Pfizer's upside potential past 2008.
The Motley Fool February 22, 2007 Ryan Fuhrmann	Dueling Fools: Pfizer Bull Rebuttal The patent expirations are an issue, but the cash is what's really important. Investors, take note.
The Motley Fool December 4, 2006 Michael Leibert	Whither Pfizer? Bad news follows the upbeat message delivered at Pfizer's R&D briefing. But with strong cash flows, a healthy dividend yield, unparalleled scale, and a discounted share price, Pfizer's risk/reward profile might look attractive to investors.
Chemistry World December 21, 2015 Phillip Broadwith	Is bigger really better? Something that's often glossed over in the aftermath of a pharmaceutical mega-merger is whether savings actually materialize, and at what cost to the future success of the businesses.
Pharmaceutical Executive March 1, 2009 Walter Armstrong	Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.
Chemistry World March 2011 Bea Perks	Editorial: At the forefront The news that most of Pfizer's 2400 employees at Sandwich, U.K. will be made redundant over the next two years was met with surprise, disappointment and anger.
The Motley Fool January 15, 2009 Robert Steyer	For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move?
Chemistry World December 8, 2015 Jennifer Newton	Pfizer to close Cambridge pain outpost Pfizer plans to shut down its Neusentis site on the outskirts of Cambridge, UK, in a move that will eliminate up to 120 jobs.
CIO October 31, 2011 Maryfran Johnson	How Pfizer's CIO Led a Transformation of the Business Pharmaceutical giant Pfizer is using IT to drive new business.
Pharmaceutical Executive June 9, 2014 Cliff Kalb	The Urge to Merge Deal making lessons for pharmaceutical companies from history's storyboard.
The Motley Fool May 17, 2004 Roger Nusbaum	Diagnosing Pfizer Can Pfizer, the pharmaceutical company, outperform the market?
The Motley Fool March 3, 2009 Brian Orelli	Pfizer Eyes Generic Growth Two partnerships in one day? Oh my!
The Motley Fool January 23, 2007 Ryan Fuhrmann	Back to the Future at Pfizer Pfizer just provided guidance for the next couple of years. The news shows that the company is willing to shake things up, but investors should remain skeptical until tangible benefits occur.
The Motley Fool September 11, 2007 Brian Lawler	Looking Forward at Pfizer With generic competition on the way for Pfizer's top drug, Lipitor, the company stepped up to the podium at the Bear Stearns Healthcare Conference this week to let investors know its plans.
CIO October 28, 2011 Kim S. Nash	Pfizer's Future Depends on IT Transformation With its business model ailing, this pharmaceutical giant tries a new IT formula, including a loyalty discount card, mobile applications aimed at consumers, and a cloud-based tablet CRM system for physicians.
The Motley Fool June 11, 2008 Brian Lawler	Dueling Fools: Pfizer Bear Is Pfizer ready for a comeback? The bearish opinion is that shares may be down, but the bleeding still isn't over.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
Chemistry World March 16, 2007	Testing Times for 'Mega-Pharma' A stern warning and gloomy forecast were delivered to the pharmaceutical industry at the Drug Discovery and Technology Summit in London.
The Motley Fool December 18, 2008 Brian Orelli	Best Stock for 2009: Pfizer Pfizer's languishing stock price has made the company so much more attractive; it could see a breakout in 2009.
Bio-IT World March 17, 2004	Pharma's Genomic Harvest How Pfizer plans to meet its goal of 20 new drug applications by 2006.
The Motley Fool October 1, 2008 Brian Orelli	Is Pfizer the Mystery Bidder? A few signals that Pfizer might be the one bidding on ImClone.
CIO October 28, 2011 Kim S. Nash	Challenging Times for Pfizer As drug patents expire, the pharmaceutical giant is investing in technology and emerging markets while cutting back on R&D and labor.
The Motley Fool February 3, 2010 Brian Orelli	Wyeth Can't Save Pfizer Not much earnings growth, but the price is right.
The Motley Fool November 17, 2008 Rich Smith	This Just In: Upgrades and Downgrades Bank of America analysts aren't terribly impressed with most drug companies. But they did give thumbs up to two.
The Motley Fool April 27, 2009 Jim Mueller	Foolish Forecast: Pfizer's Out of the Starting Gate In advance of earnings, analyst's expect revenue down 6%, but none are saying to dump the stock.
The Motley Fool February 10, 2006 Brian Gorman	Pfizer in Pflux The company is working on its transition, but things still look fairly murky for investors.
The Motley Fool April 20, 2007 Ryan Fuhrmann	Discerning Pfizer's Pfuture The company is undergoing a transformation, but that doesn't mean it isn't worth a look from investors.
The Motley Fool June 15, 2010 Brian Orelli	Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer.
Chemistry World May 19, 2014 Phillip Broadwith	AstraZeneca refuses Pfizer's 'final' offer The US giant has described this proposal, valuing AZ at 70 billion pounds, as 'final' and says it 'cannot be increased'.
Bio-IT World December 10, 2002 Jim Hall	21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives.
The Motley Fool April 21, 2008 Brian Lawler	Pfizer Is Still Floundering Generic competition keeps pounding away at its sales and profits.
The Motley Fool October 15, 2007 Brian Lawler	Save Your Cash, Pfizer A multibillion-dollar stake in Sanofi wouldn't fix Pfizer's problems. Investors, take note.